Latest & greatest articles for colorectal cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for colorectal cancer

21. Cancer Screening: Interventions Engaging Community Health Workers – Colorectal Cancer

or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).ti,ab. 4. 2 or 3 5. 1 and 4 6. colonography, computed tomographic/ or colonoscopy/ or endoscopy, gastrointestinal/ or sigmoidoscopy/ or ((occult blood.ti,ab. or occult blood/) and (feces/ or (faeces or fecal or faecal or colorectal).ti,ab.)) or (enema/ and barium sulfate/) 7. mammography/ or mammogra*.ti,ab. 8. (colonography or colonoscop* or fobt or sigmoidoscop*).ti,ab (...) or screening or "early detection of cancer").mp. 2. ((neoplasm* or ductal breast carcinoma* or "hereditary breast and ovarian cancer syndrome") and (diagnosis or prevention)).mp. [mp=title, abstract, heading word, table of contents, key concepts, original title, tests & measures] 3. ((adenoma* or neoplasia or cancer* or neoplasm* or tumo?r* or carcinoma* or adenocarcinoma*) and (breast or cervical or cervix or colon or colorectal or crc)).mp. 4. 2 or 3 5. 1 and 4 6. ((colonography or colonoscopy

2020 Community Preventive Services Task Force

22. Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. (Abstract)

Deep learning for prediction of colorectal cancer outcome: a discovery and validation study. Improved markers of prognosis are needed to stratify patients with early-stage colorectal cancer to refine selection of adjuvant therapy. The aim of the present study was to develop a biomarker of patient outcome after primary colorectal cancer resection by directly analysing scanned conventional haematoxylin and eosin stained sections using deep learning.More than 12 000 000 image tiles from patients (...) prepared in Norway. All cohorts included only patients with resectable tumours, and a formalin-fixed, paraffin-embedded tumour tissue block available for analysis. The primary outcome was cancer-specific survival.828 patients from four cohorts had a distinct outcome and were used as a training cohort to obtain clear ground truth. 1645 patients had a non-distinct outcome and were used for tuning. The biomarker provided a hazard ratio for poor versus good prognosis of 3·84 (95% CI 2·72-5·43; p<0·0001

2020 Lancet

23. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. (Abstract)

Classification of Disease in the patient register (in the country in question) or one such record plus a colorectal biopsy report with a morphology code suggestive of inflammatory bowel disease. For every patient with UC, we selected matched reference individuals from the total population registers of Denmark and Sweden, who were matched for sex, age, birth year, and place of residence. We used Cox regression to compute hazard ratios (HRs) for incident CRC, and for CRC mortality, taking tumour stage (...) Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Ulcerative colitis (UC) is a risk factor for colorectal cancer (CRC). However, available studies reflect older treatment and surveillance paradigms, and most have assessed risks for incident CRC without taking surveillance and lead-time bias into account, such as by assessing CRC incidence by tumour stage, or stage-adjusted mortality from CRC. We aimed to compare both overall and country-specific risks of CRC

2020 Lancet

24. Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

; 51Introduction Colonoscopy is the key examination technique in colorectal cancer (CRC) screening programs for detection and treatment of early precursor lesions and timely diagnosis of colorectal cancer [1,2]. The quality of colonoscopy, which depends on both bowel preparation and examination technique, is the main determining factor that drives the protective effect of this invasive examination in decreasing the societal disease burden [3–5]. Over the last 15 years, several new techniques to improve polyp (...) in the surveillance of SPS patients. However, its routine use must bebalanced against practical considerations. Bisschops Raf et al. Advanced imaging for detection and differentiation of colorectal neoplasia: ESGE Guideline – Update 2019 … Endoscopy 2019; 51Detection and differentiation ofcolorectal neoplasia in inflammatory bowel disease (IBD) Patients with long-standing or extensive ulcerative colitis (UC) or Crohn’s disease are at an increased risk of developing CRC compared to the average risk population

2020 European Society of Gastrointestinal Endoscopy

25. British Society of Gastroenterology/Association of Coloproctology of Great Britain and Ireland/Public Health England post-polypectomy and post-colorectal cancer resection surveillance guidelines Full Text available with Trip Pro

Sussex Hospitals NHS Foundation Trust, Chichester, UK. 6 Colorectal surgery, Raigmore Hospital, Inverness, UK. 7 Gastroenterology, Cardiff and Vale NHS Trust, Cardiff, UK. 8 Histopathology, Nottingham University Hospitals, Nottingham, UK. 9 Family History of Bowel Cancer Clinic, West Middlesex University Hospital, London, UK. 10 Imperial College, London, UK. 11 Histopathology, University College London, London, UK. 12 Centre for Medical Imaging, UCL, London, UK. 13 Endoscopy, St Marks Hospital (...) Abstract These consensus guidelines were jointly commissioned by the British Society of Gastroenterology (BSG), the Association of Coloproctology of Great Britain and Ireland (ACPGBI) and Public Health England (PHE). They provide an evidence-based framework for the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 years and over. They are the first guidelines that take into account the introduction of national bowel cancer screening. For the first time, they also

2020 EvidenceUpdates

26. FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109)

FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109) - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Welcome to the new PubMed. For legacy PubMed go (...) your collection: Name must be less than 100 characters Choose a collection: Unable to load your collection due to an error Add Cancel Add to My Bibliography My Bibliography Unable to load your delegates due to an error Add Cancel Actions Cite Share Permalink Copy Page navigation J Clin Oncol Actions , 37 (35), 3401-3411 2019 Dec 10 FOLFOXIRI Plus Panitumumab As First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer: The Randomized, Open-Label, Phase II VOLFI Study (AIO KRK0109

2020 EvidenceUpdates

27. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline

repair genes in hereditary nonpolyposis colorectal cancer patients with small bowel cancer: International Society for Gastrointestinal Hereditary Tumours Collaborative Study. Clinical Cancer Res 2006; 12: 3389–3393 [80] Rodriguez-Bigas MA, Vasen HF, Lynch HT et al. Characteristics of small bowel carcinoma in hereditary nonpolyposis colorectal carci- noma. International Collaborative Group on HNPCC. Cancer 1998; 83: 240–244 [81] SchulmannK,BraschFE,KunstmannEetal.HNPCC-associatedsmall bowel cancer (...) cancer mortality in first- degree relatives ofearly-onset colorectal cancer cases. Dis Colon Rectum 2002; 45: 681–686 [107] Kune GA, Kune S, Watson LF. The role of heredity in the etiologyof large bowel cancer: data from the Melbourne Colorectal Cancer Study. World J Surg 1989; 13: 124–129 ; discussion 9–31 [108] Samadder NJ, Smith KR, Hanson H et al. Increased riskofcolorectal canceramongfamilymembersofallages,regardlessofageofindex case at diagnosis. Clin Gastroenterol Hepatol 2015; 13: 2305–2311

2020 European Society of Gastrointestinal Endoscopy

28. 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT Full Text available with Trip Pro

3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found (...) Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK 6 Department of Oncology and Palliative Care, Zealand University Hospital, Naestved, Denmark 7 Vall d’Hebron University Hospital and Institute of Oncology, Universitat Autònoma de Barcelona, Barcelona, Spain 8 Australasian Gastro-Intestinal Trials Group, Camperdown, NSW, Australia 9 University of Uppsala, Uppsala, Sweden 10 Oncology Clinical Trials Office, Department of Oncology, University of Oxford, Oxford, UK 11 Beatson

2020 NIHR HTA programme

29. Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Full Text available with Trip Pro

Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Whole-body MRI compared with standard pathways for staging metastatic disease in lung and colorectal cancer: the Streamline diagnostic accuracy studies Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} This study found that, for both cancers, whole-body MRI was as sensitive as standard staging. {{author}} {{($index , , , , , , , , , , , , , , , , & . Stuart A Taylor 1, * , Susan Mallett 2 , Anne Miles 3 , Stephen Morris 4 , Laura Quinn 2 , Caroline S Clarke 5 , Sandy Beare 6 , John Bridgewater 7 , Vicky Goh

2020 NIHR HTA programme

30. Encorafenib (Braftovi) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation

Encorafenib (Braftovi) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation - Repository of AIHTA GmbH English | Browse - - - Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC (...) ) with a BRAF V600E mutation Grössmann, N. (2020): Encorafenib (Braftovi®) in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation. Oncology Fact Sheet Nr. 7. Preview - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. , oder 74kB Item Type: Oncology Fact Sheets Subjects: > > > > > Language: English Series Name: Oncology Fact Sheet Nr. 7 Deposited on: 02 Jun 2020 15:51 Last Modified: 15 Jul 2020 18:01 Repository

2020 Austrian Institute of Health Technology Assessment

31. Investigating the Effect of Self-Care Training on Life Expectancy and Quality of Life in Patients with Gastrointestinal Cancer under Radiotherapy. Full Text available with Trip Pro

Investigating the Effect of Self-Care Training on Life Expectancy and Quality of Life in Patients with Gastrointestinal Cancer under Radiotherapy. A huge amount of the efforts made by health teams is dedicated to caring for cancer patients. This study has aimed to investigate the effect of self-care training on life expectancy and quality of life (QOL) in patients with gastrointestinal cancer who were under radiotherapy.In this clinical trial, 50 patients were selected using the block (...) training improved the QOL and life expectancy of patients with gastrointestinal cancer who were under radiotherapy. Therefore, self-care training is recommended to improve the QOL and the life expectancy of cancer patients.

2019 Asia-Pacific journal of oncology nursing Controlled trial quality: uncertain

32. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy Full Text available with Trip Pro

Have inflammatory bowel disease Have hereditary syndromes that increase the risk of colorectal cancer, such as Lynch syndrome and familial adenomatous polyposis. Several factors influence individuals’ decisions whether to be screened, even when they are presented with the same information: Variation in an individual’s values and preferences A close balance of benefits versus harms and burdens (for example, for a baseline risk of 3%, FIT every two years results in five fewer deaths from colorectal (...) recommendations: an international comparison of high income countries . NHS. Bowel scope screening. . Navarro M , Nicolas A , Ferrandez A , Lanas A . Colorectal cancer population screening programs worldwide in 2016: An update . Levin TR , Corley DA , Jensen CD , et al . Effects of organized colorectal cancer screening on cancer incidence and mortality in a large community-based population . Cancer Research UK. Bowel cancer incidence statistics. . Danckert B FJ, Engholm G, Hansen HL, et al. NORDCAN: Cancer

2019 BMJ Rapid Recommendations

33. Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma

Bevacizumab (Zirabev) - colorectal cancer, non-small cell lung cancer, peritoneal cancer, glioblastoma Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity

2019 Health Canada - Drug and Health Product Register

34. Colorectal Cancer

of Colorectal Liver Metastases 111 7.4.3. Tumor Markers 113 7.4.4. Specific Diagnostics for Rectal Cancer 114 7.5. Surgical Therapy with Curative Intention 117 7.5.1. Intraoperative Staging 117 7.5.1.1. Intra-Operative Pathological Examination 117 7.5.2. Radical Surgical Therapy of Colon Cancer 118 7.5.2.1. Extent of Lymph Node Dissection: 118 7.5.2.2. Complete Mesocolic Excision (CME) 120 7.5.2.3. Local Ablative Therapies for Liver Metastases 121 7.5.2.3.1. Radio-Frequency Ablation (RFA) 121 7.5.2.3.2 (...) (Hereditary Non-Polyposis Colorectal Cancer) 135 7.7.8. Cancers in Familial Adenomatous Polyposis (FAP) 136 1.1 Editors © German Guideline Program in Oncology | Evidenced-based Guideline for Colorectal Cancer | Version 2.1 | Januar 2019 6 7.7.9. Cancers in Ulcerative Colitis 136 7.8. Postoperative Histopathological Examination 137 7.8.1. Cancer-Grading Based on MSI-H 137 7.8.2. Number of LN to be Removed 138 7.8.3. Relevance of Distance Between the Tumor Margin and Resection Area of the Mesocolon in Colon

2019 German Guideline Program in Oncology

35. Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer

Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer Endoscopic surveillance after surgical or endoscopic resection for colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Digestive Oncology (ESDO) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-0831-2522 Endoscopy 2019; 51: 266–277 © Georg Thieme Verlag KG Stuttgart· New York Explore the ESGE (...) website Menu Contact us +49-89-9077936-0 Follow us © 2004 - 2019 European Society of Gastrointestinal Endoscopy (ESGE). All Rights Reserved. |

2019 European Society of Gastrointestinal Endoscopy

36. Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer

Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer Endoscopic management of Lynch syndrome and of familial risk of colorectal cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-1016-4977 | Endoscopy 2019; 51:1082–1093 Published online: 9.10.2019 © Georg Thieme Verlag KG Stuttgart · New York Explore the ESGE website Menu Contact us +49 (...) -89-9077936-0 Follow us © 2004 - 2019 European Society of Gastrointestinal Endoscopy (ESGE). All Rights Reserved. |

2019 European Society of Gastrointestinal Endoscopy

37. Advanced imaging for detection and differentiation of colorectal neoplasia

Advanced imaging for detection and differentiation of colorectal neoplasia Advanced imaging for detection and differentiation of colorectal neoplasia: European Society of Gastrointestinal Endoscopy (ESGE) Guideline – Update 2019 – European Society of Gastrointestinal Endoscopy (ESGE) +49-89-9077936-11 Menu DOI https://doi.org/10.1055/a-1031-7657 | Endoscopy 2019; 51: 1155–1179 Published online: 11.11.2019 © Georg Thieme Verlag KG Stuttgart · New York Explore the ESGE website Menu Contact us +49 (...) -89-9077936-0 Follow us © 2004 - 2019 European Society of Gastrointestinal Endoscopy (ESGE). All Rights Reserved. |

2019 European Society of Gastrointestinal Endoscopy

38. Variation in post-colonoscopy colorectal cancer across colonoscopy providers in English National Health Service: population based cohort study. Full Text available with Trip Pro

for colonoscopies performed under the NHS bowel cancer screening programme (593/16 640, 3.6%), while they were higher for those conducted by non-NHS providers (187/2009, 9.3%). Rates were higher in women, in older age groups, and in people with inflammatory bowel disease or diverticular disease, in those with higher comorbidity scores, and in people with previous cancers. Substantial variation in rates among colonoscopy providers remained after adjustment for case mix.Wide variation exists in PCCRC-3yr rates (...) across NHS colonoscopy providers in England. The lowest incidence was seen in colonoscopies performed under the NHS bowel cancer screening programme. Quality improvement initiatives are needed to address this variation in rates and prevent colorectal cancer by enabling earlier diagnosis, removing premalignant polyps, and therefore improving outcomes.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group

2019 BMJ

39. Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. Full Text available with Trip Pro

Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. The purpose of this guidance statement is to guide clinicians on colorectal cancer screening in average-risk adults.This guidance statement is derived from a critical appraisal of guidelines on screening for colorectal cancer in average-risk adults and the evidence presented in these guidelines. National guidelines published in English between 1 June 2014 and 28 May (...) should screen for colorectal cancer in average-risk adults between the ages of 50 and 75 years.Clinicians should select the colorectal cancer screening test with the patient on the basis of a discussion of benefits, harms, costs, availability, frequency, and patient preferences. Suggested screening tests and intervals are fecal immunochemical testing or high-sensitivity guaiac-based fecal occult blood testing every 2 years, colonoscopy every 10 years, or flexible sigmoidoscopy every 10 years plus

2019 Annals of Internal Medicine

40. Bowel cancer screening: imaging use

screening: imaging use Information about imaging practice standards for bowel cancer screening of individuals unsuitable for a colonoscopy. Published 1 November 2012 Last updated 14 October 2019 — From: Documents Ref: PHE publications gateway number: GW-810 HTML Details This publication explains the use of whole colon imaging as an alternative to a colonoscopy as part of the NHS Bowel Cancer Screening Programme ( 14 October 2019 Added new guidelines on CTC imaging in NHS bowel cancer screening. 1 (...) Bowel cancer screening: imaging use Bowel cancer screening: imaging use - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Register by 26 November to vote in the General Election on 12 December. Guidance Bowel cancer

2019 Public Health England